http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017157228-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_eb61fc3ba47905ec9048959f43994b02
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-572
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-645
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-40
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-07049
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-4748
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y207-10001
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001106
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001157
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001182
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-001186
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1276
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-12
filingDate 2015-07-17-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d86a7269b37e2ad75a1f07b87db29c4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_066af968e9cf073cb7dcf8f34a8f7e92
publicationDate 2017-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-2017157228-A1
titleOfInvention Immunogenic Polypeptide Composed of HLA-B7 Restricted Tumor Antigen-Derived Optimized Cryptic Peptides, and Uses Thereof
abstract The invention pertains to an optimized chimeric polypeptide for use in HLA-337 cancer patients, which comprises four optimized peptides derived from cryptic tumor epitopes (CEA, TERT, MAGE and HER-2/neu) to enhance their immunogenicity.
priorityDate 2014-07-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2440575-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013266598-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012142894-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011256163-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2440575-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10024868-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007073768-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID66577194
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID19649
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395500
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226393795

Total number of triples: 45.